Guide

NDI Notification Readiness: Building a 21 CFR 190.6 Dossier FDA Will Accept

Any dietary ingredient not marketed in the United States before October 15, 1994 is a new dietary ingredient (NDI) under DSHEA. Before a supplement containing that ingredient can be marketed, the manufacturer or distributor must file a 75-day pre-market notification with FDA under 21 CFR 190.6. The notification is not an approval — FDA reviews and either issues no objection, objects, or requests more information. Historically about three out of four NDI notifications draw an objection or incomplete response, almost always because the safety dossier or history-of-use evidence is thin. This guide maps what a defensible NDI looks like and where V5 carries the supporting evidence.

Start free trial Free trial, no credit card, onboard in days, not months.

What counts as a new dietary ingredient

Under DSHEA §413 and 21 CFR 190.6, a dietary ingredient is "new" if it was not marketed in the US as a dietary supplement (or food) before October 15, 1994. Reformulations using only grandfathered ingredients (the "old dietary ingredient" list, which is informal and contested) do not trigger NDI. A new botanical extract, a new synthetic, a chemically altered form of an existing ingredient, or an existing ingredient at a substantially higher dose all generally trigger NDI. FDA's 2016 draft guidance is the working interpretation — note it is still draft, but FDA reviews against it.

The four-pillar safety dossier FDA actually reads

An accepted NDI dossier typically has four pillars. (1) Identity: chemical or botanical identification, manufacturing method, full specification including impurity and contaminant limits. (2) History of safe use: documented human exposure at the proposed dose, ideally in the population the supplement will market to. (3) Toxicology: in vitro, animal, and (where available) human safety data sized to the proposed exposure. (4) Proposed use conditions: target population, dose, duration, label warnings. FDA objections cluster on pillars 2 and 3 — history-of-use that does not match the proposed dose, or toxicology that does not cover the proposed exposure duration.

The 75-day clock and what FDA actually does with it

21 CFR 190.6 gives FDA 75 days to review the notification before the ingredient can be marketed. FDA does not approve — it either takes no action (the ingredient can be marketed at day 76), objects (with a letter explaining why), or requests additional information (which can pause the clock). A notification can be withdrawn and re-filed if the manufacturer wants to address gaps before objection. Objection letters become public on FDA's NDI database — a notification objected once carries reputational and litigation risk into any future filing.

GRAS vs NDI — when self-determination is the right path

An ingredient that is GRAS (Generally Recognized As Safe) for its intended use under 21 CFR 170.30 can be marketed in a supplement without an NDI notification, on the theory that GRAS substances are not "new" in the relevant safety sense. The practical question is whether the GRAS self-determination would survive FDA challenge. A GRAS conclusion supported by published safety literature and convened-expert-panel review is generally defensible; a thin self-affirmation is not. Many manufacturers pursue both paths — GRAS for the food use and NDI for the supplement use — to maximise legal robustness.

A 120-day NDI notification readiness path

Days 1–20: identity and specification — full chemical/botanical ID, manufacturing description, impurity and contaminant profile. Days 21–50: history-of-safe-use evidence — literature search, market presence at the proposed dose, exposure analysis. Days 51–80: toxicology dossier — in vitro and animal safety data sized to the proposed exposure, gap analysis against ICH and OECD norms. Days 81–100: proposed-use definition and label warnings. Days 101–115: dossier integration and FDA-style internal review. Days 116–120: notification assembly and filing.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

NDI Notification

An NDI (New Dietary Ingredient) Notification is the 75-day premarket safety filing required under FD&C Act §413 and 21 CFR 190.6 before a dietary supplement containing a 'new' dietary ingredient — one

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

NDI dossier control

Four-pillar evidence with version history.

Ingredient-level NDI status

NDI gate surfaced at the spec stage.

FDA RFI workflow

75-day clock with milestone checkpoints.

Industries this hits hardest

Dietary supplements

Frequently asked

Is an NDI notification an FDA approval?

No. FDA reviews and either takes no objection, objects, or requests more information. "No objection" means the manufacturer can market — it does not certify the ingredient is safe. The manufacturer remains responsible for the safety determination.

Why do most NDI notifications get an objection?

FDA's published objection letters cluster on insufficient history-of-safe-use evidence at the proposed dose, insufficient toxicology for the proposed exposure duration, or identity gaps (no manufacturing description, no impurity profile). The chemistry is rarely the problem — the safety dossier sizing is.

Can we GRAS-affirm instead of filing NDI?

If the ingredient has a credible GRAS conclusion for its intended use, it can be marketed in a supplement without NDI. The practical question is whether the GRAS would survive FDA challenge — a self-affirmation without expert panel review and published literature is fragile. Many filers pursue both paths.

What happens if we market a new ingredient without filing NDI?

FDA can treat the product as adulterated under FDCA §402(f) and issue a warning letter, seizure, or injunction. The legal and reputational cost dwarfs the cost of filing — every supplement enforcement summary contains warning letters for unfiled NDIs.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →